Gossamer Bio (GOSS) Earnings
Price: $0.83
Market Cap: $188.57M
Market Cap: $188.57M
Revenue (TTM): $114.70M
Net Income: $-56.53M
Net Income: $-56.53M
P/E Ratio: -3.32
EPS (TTM): $-0.25
EPS (TTM): $-0.25
Earnings Dates
Gossamer Bio (GOSS) reports its earnings quarterly. Here are the key details:
Next Earnings Date
- Date: May 06, 2025
- Time of Day: Before Market Open
- Estimated EPS: $-0.19
Last Earnings Report
- Date: March 13, 2025
- EPS: $-0.15
- EPS Estimate: $-0.17
Gossamer Bio's next earnings report is scheduled for May 06, 2025.
In its last earnings report on March 13, 2025, Gossamer Bio reported earnings per share (EPS) of $-0.15, compared to an estimated EPS of $-0.17. The company reported revenue of $9.38M, compared to an estimated revenue of $6.83M.
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2021 | 2022-03-03 | N/A | N/A |
| Read Transcript | Q3 | 2021 | 2021-11-08 | N/A | N/A |
| Read Transcript | Q2 | 2021 | 2021-08-09 | N/A | N/A |
| Read Transcript | Q4 | 2020 | 2021-02-27 | N/A | N/A |
| Read Transcript | Q3 | 2020 | 2020-11-10 | N/A | N/A |
| Read Transcript | Q1 | 2020 | 2020-05-12 | N/A | N/A |
| Read Transcript | Q3 | 2019 | 2019-11-12 | N/A | N/A |
| Read Transcript | Q2 | 2019 | 2019-08-10 | N/A | N/A |
| Read Transcript | Q1 | 2019 | 2019-05-14 | N/A | N/A |
Earnings History
| Date | EPS | EPS Estimate | Revenue | Revenue Estimate |
|---|---|---|---|---|
| March 13, 2025 | $-0.15 | $-0.17 | $9.38M | $6.83M |
| November 07, 2024 | $-0.14 | $-0.18 | $9.48M | $6.83M |
| August 12, 2024 | $0.22 | $0.23 | $95.84M | $114.29M |
| May 07, 2024 | $-0.19 | $-0.19 | $- | $- |
| March 05, 2024 | $-0.21 | $-0.20 | $6.78M | $- |
| November 09, 2023 | $-0.21 | $-0.20 | $- | $- |
| August 08, 2023 | $-0.45 | $-0.49 | $- | $- |
| May 09, 2023 | $-0.52 | $-0.55 | $- | $- |
| March 17, 2023 | $-0.59 | $-0.62 | $- | $- |
| November 03, 2022 | $-0.65 | $-0.66 | $- | $- |
| August 09, 2022 | $-0.74 | $-0.67 | $- | $- |
| May 10, 2022 | $-0.76 | $-0.77 | $- | $- |
| March 03, 2022 | $-0.74 | $-0.74 | $- | $- |
| November 08, 2021 | $-0.80 | $-0.78 | $- | $- |
| August 09, 2021 | $-0.80 | $-0.77 | $- | $- |
| May 06, 2021 | $-0.78 | $-0.80 | $- | $- |
| February 25, 2021 | $-0.88 | $-0.80 | $- | $- |
Annual Earnings
Annual Revenue
$114.70M
Fiscal Year 2024Annual Net Income
$-56.53M
Fiscal Year 2024Annual EPS
$-0.25
Fiscal Year 2024Quarterly Earnings
Revenue
$9.38M
Quarter Ending December 31, 2024Net Income
$-33.03M
Quarter Ending December 31, 2024EPS
$-0.15
Quarter Ending December 31, 2024Earnings Metrics
Earnings Yield
-27.62%
Year Ending December 31, 2024P/E Ratio
-3.62
Year Ending December 31, 2024Revenue Per Share
$0.51
Year Ending December 31, 2024Earnings Yield (TTM)
-30.11%
Trailing Twelve MonthsP/E Ratio (TTM)
-3.32
Trailing Twelve MonthsRevenue Per Share (TTM)
$0.51
Trailing Twelve MonthsFrequently Asked Questions
Gossamer Bio's next earnings date is scheduled for May 06, 2025. The earnings call is expected to take place before market open.
In its last earnings report on March 13, 2025, Gossamer Bio reported earnings per share (EPS) of $-0.15, compared to an estimated EPS of $-0.17. The company reported revenue of $9.38M, compared to an estimated revenue of $6.83M.
Gossamer Bio's current Price-to-Earnings (P/E) ratio is -3.62. The trailing twelve months (TTM) P/E ratio is -3.32. The P/E ratio is a valuation metric that compares a company's current share price to its earnings per share (EPS). A higher P/E ratio suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E ratio.
For the fiscal year ending December 31, 2024, Gossamer Bio reported total revenue of $114.70M and net income of $-56.53M. This represents a net profit margin of -0.492829182.
Gossamer Bio's earnings yield is -27.62%. The earnings yield is the inverse of the P/E ratio and represents the percentage of each dollar invested in the stock that was earned by the company.
Gossamer Bio's return on equity (ROE) is -191.67%. ROE is a measure of financial performance calculated by dividing net income by shareholders' equity. It measures how effectively management is using a company's assets to create profits.
Gossamer Bio's gross profit margin is 100.00%. This indicates that for every dollar of revenue, the company retains $1.00 as gross profit after accounting for the cost of goods sold.